A share price of Inhibrx Inc [INBX] is currently trading at $34.97, up 0.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INBX shares have lost -0.31% over the last week, with a monthly amount drifted -0.54%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results. In a post published today on Yahoo Finance, Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.
From an analyst’s perspective:
Inhibrx Inc [NASDAQ: INBX] stock has seen the most recent analyst activity on January 23, 2024, when JMP Securities downgraded its rating to a Mkt Perform. Previously, SMBC Nikko started tracking the stock with Outperform rating on March 16, 2022, and set its price target to $40. On September 21, 2021, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $46 on the stock. Evercore ISI initiated its recommendation with a Outperform and recommended $30 as its price target on September 14, 2020. Credit Suisse started tracking with a Outperform rating for this stock on September 14, 2020, and assigned it a price target of $26.
Inhibrx Inc experienced fluctuations in its stock price throughout the past year between $14.31 and $39.79. Inhibrx Inc [NASDAQ: INBX] shares were valued at $34.97 at the most recent close of the market.
Analyzing the INBX fundamentals
Trailing Twelve Months sales for Inhibrx Inc [NASDAQ:INBX] were 1.80M which represents 496.35% growth. Gross Profit Margin for this corporation currently stands at -0.14% with Operating Profit Margin at -121.79%, Pretax Profit Margin comes in at -133.18%, and Net Profit Margin reading is -133.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -5.9 and Total Capital is -0.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.69 points at the first support level, and at 34.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.19, and for the 2nd resistance point, it is at 35.41.
Inhibrx Inc [INBX] reported earnings per share of -$1.73 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.04/share, meaning a difference of -$0.69 and a surprise factor of -66.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.1 per share as compared to estimates of -$1.01 per share, a difference of -$0.09 representing a surprise of -8.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inhibrx Inc [NASDAQ:INBX] is 5.25. Also, the Quick Ratio is 5.25, while the Cash Ratio stands at 4.94. Considering the valuation of this stock, the price to sales ratio is 920.68, the price to book ratio is 38.08.
Transactions by insiders
Recent insider trading involved VIKING GLOBAL INVESTORS LP, 10% Owner, that happened on Aug 28 ’23 when 0.51 million shares were purchased.
